ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3103

Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies

Shuichiro Nakabo1, Koichiro Ohmura1, Kosaku Murakami1, Ran Nakashima1, Moritoshi Furu2, Masahiro Ishikawa2, Motomu Hashimoto2, Yoshitaka Imura1, Naoichiro Yukawa1, Hajime Yoshifuji1, Hiromu Ito2, Takao Fujii2 and Tsuneyo Mimori1,2, 1Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Anti-carbamylated protein antibody (anti-CarP) is seen in 45% of
rheumatoid arthritis (RA) patients [1]. The precise target antigen (Ag) of
anti-CarP had not been elucidated, since the authors of the first report used
fetal calf serum (FCS) as target Ag which contains various kind of proteins. Although
several proteins have been reported to be target Ags of anti-CarP, the repertoire
of anti-CarP has not been fully understood. In addition, all reported carbamylated
Ags are also known as citrullinated Ags, and carbamylation-specific Ag has not been
reported. Since the largest fraction of FCS is albumin, we hypothesized that human
albumin (ALB) is one of target Ags of anti-CarP. The purpose of this study is to
demonstrate whether anti-carbamylated ALB antibody (anti-car-ALB) is detected
in RA and to evaluate its clinical importance.

Methods: ALB and FCS were carbamylated by potassium cyanate. ALB was also
citrullinated by peptidyl arginine deiminase. We established in house ELISA
systems of anti-carbamylated FCS antibody (anti-car-FCS), anti-car-ALB, and anti-citrullinated
ALB antibody (anti-cit-ALB) as previously described [1]. Sera and clinical data
of 455 RA patients were obtained from KURAMA database which was established to
store clinical information and specimens from RA patients in Kyoto University. Inhibition
ELISA was done by 8 representative sera, in which they were pre-incubated with
increasing concentration of unmodified FCS, car-FCS, car-ALB, or cit-ALB and
tested for reactivity against car-FCS.

Results: The sensitivity of anti-car-FCS, anti-car-ALB, and anti-cit-ALB were
27.0%, 44.2%, and 7.3%, respectively (Table 1). Positive result of anti-car-ALB
was related to bone damage and smoking (Table 2). Inhibition ELISA showed
anti-car-FCS was inhibited by car-ALB, but not by cit-ALB (Figure 1A). Strength
of inhibition by car-ALB was different among sera (Figure 1B). The titer of
anti-car-FCS and anti-car-ALB showed good correlation (rho=0.63), but anti-CCP
did not correlate with anti-car-ALB (rho=0.28) or anti-cit-ALB (rho=0.16).

Conclusion: Anti-car-ALB was more sensitive than anti-car-FCS for diagnosing RA and
correlated with bone damage and smoking. Car-ALB is one of the target Ags of
anti-CarP. This is the first report of carbamylation-specific Ag.

Reference: [1] Shi J. Proc Natl Acad Sci U S A. 2011; 108: 17372.


Disclosure: S. Nakabo, None; K. Ohmura, None; K. Murakami, None; R. Nakashima, None; M. Furu, None; M. Ishikawa, None; M. Hashimoto, None; Y. Imura, None; N. Yukawa, None; H. Yoshifuji, None; H. Ito, None; T. Fujii, None; T. Mimori, None.

To cite this abstract in AMA style:

Nakabo S, Ohmura K, Murakami K, Nakashima R, Furu M, Ishikawa M, Hashimoto M, Imura Y, Yukawa N, Yoshifuji H, Ito H, Fujii T, Mimori T. Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/carbamylated-human-albumin-is-one-of-the-target-antigens-of-anti-carbamylated-protein-antibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/carbamylated-human-albumin-is-one-of-the-target-antigens-of-anti-carbamylated-protein-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology